Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib -resistant gastrointestinal stromal tumor (GIST) in January 2006.

2024年8月8日 · What is sunitinib? Sunitinib is used to treat certain types of advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys. Sunitinib may also be used for purposes not listed in this medication guide.

Sunitinib is used to treat gastrointestinal stromal tumors (GIST; a type of tumor that grows in the stomach, intestine (bowel), or esophagus (tube that connects the throat with the stomach) in people with tumors that were not treated successfully with imatinib (Gleevec) or people who cannot take imatinib.

舒尼替尼 （INN： Sunitinib），商标名 索坦 （Sutent），是一种口服的小分子多靶点 受体酪氨酸激酶 抑制剂，2006年1月26日被 FDA 批准用于治疗对标准疗法没有响应或不能耐受的 胃肠道基质肿瘤 和转移性 肾细胞癌。 舒尼替尼是第一种被批准用于同时治疗两种类型 癌症 的药物。 [1] 舒尼替尼通过靶向多个受体酪氨酸激酶来抑制细胞信号。 这些 受体 包括：血小板衍化生长因子R链（PDGF-R）和 血管内皮生长因子 受体（VEGFRs），它们在肿瘤的 血管生成 和细胞增殖中 …

2024年11月29日 · Sutent is a prescription medicine used to treat certain types of advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys. It is not known if Sutent is safe and effective in children. Sutent can cause severe or fatal effects on your liver.

舒尼替尼（Sunitinib，Sutent）是一种新型多靶向性的治疗肿瘤的口服药物。 舒尼替尼的首要开发目标为，用于治疗对标准疗法没有响应或不能耐受之胃肠道基质肿瘤和转移性肾细胞癌。

SUNITINIB (soo NI ti nib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat specific digestive tract tumors called GISTs, advanced kidney cancer, and certain pancreatic neuroendocrine tumors.

舒尼替尼（Sunitinib，商品名Sutent，也称索坦）是一种新型多靶向性的口服药物，广泛用于治疗多种病症。 目前舒尼替尼已经在国内上市，本文就舒尼替尼的适应症、用法用量、副作用、禁忌、临床疗效等进行了详细说明。

Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits certain receptor tyrosine kinases (RTKs). These include vascular endothelial growth factor receptors (VEGFR type 1 and 2), platelet-derived growth factor receptors (PDGFR-alpha and PDGFR-beta), stem cell factor receptor (KIT) …

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib -resistant gastrointestinal stromal tumor (GIST).